San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
DexCom has long-term tailwinds given the continued growth of the global diabetes market, mainly due to growing levels of obesity. The emerging and already huge GLP-1 weight loss sector could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback